MK-2048 is a second-generation HIV-1 integrase inhibitor. It’s designed to be active against HIV, including strains resistant to first-generation integrase inhibitors like raltegravir and elvitegravir. MK-2048 has been investigated for use in vaginal rings as a pre-exposure prophylaxis (PrEP) for HIV prevention. It is grouped under the following drug class(es): HIV-1 Integrase Inhibitors. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include MK2048. Its PubChem CID is 54698642.
MK-2048
| CAS No | 869901-69-9 |
|---|---|
| Molecular Formula | C21H21ClFN5O4 |
| Molecular Weight | 461.90 g/mol |
| Synonyms | (13S)-5-[(3-chloro-4-fluorophenyl)methyl]-11-ethyl-8-hydroxy-N,13-dimethyl-6,10-dioxo-1,4,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2(7),3,8-triene-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
MK-2048 is a second-generation HIV-1 integrase inhibitor. It's designed to be active against HIV, including strains resistant to first-generation integrase inhibitors like raltegravir and elvitegravir.
The listed CAS number is 869901-69-9.
The listed molecular formula is C21H21ClFN5O4.
The listed molecular weight is 461.90 g/mol.
(13S)-5-[(3-chloro-4-fluorophenyl)methyl]-11-ethyl-8-hydroxy-N,13-dimethyl-6,10-dioxo-1,4,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2(7),3,8-triene-3-carboxamide.
The source lists MK2048.